Amicus Therapeutics Inc
$0
0%
2026-07-22 08:04:01
amicusrx.com
NGM: FOLD
Explore Amicus Therapeutics Inc stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$4.55 B
Current Price
$0
52W High / Low
$14.5 / $5.92
Stock P/E
—
Book Value
$0.88
Dividend Yield
—
ROCE
4.84%
ROE
-12.02%
Face Value
—
EPS
$-0.09
Exp Qtr EPS
—
Sector
Healthcare
FOLD — Monthly Price History
Adjusted close price · Hover to see price & month
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Vertex Pharmaceuticals Incorporated | $451.63 | 26.79 | $114.63 B | — | — | 0.24% | $507.92 / $362.5 | $76.18 |
| 2. | Regeneron Pharmaceuticals, Inc. | $675.19 | 15.81 | $69.94 B | 0.56% | 10.23% | 14.32% | $821.11 / $541 | $295.71 |
| 3. | Revolution Medicines, Inc. | $183.29 | — | $38.94 B | — | -57.28% | -54.06% | $193.82 / $34 | $8.28 |
| 4. | Alnylam Pharmaceuticals, Inc. | $271.37 | 62.78 | $36.24 B | — | 14.33% | 98.29% | $495.55 / $266.27 | $5.96 |
| 5. | Roivant Sciences Ltd. | $34.96 | — | $33.71 B | — | -21.06% | -6.85% | $37 / $10.9 | $6.28 |
| 6. | Royalty Pharma plc | $58.42 | 40.45 | $33.47 B | 1.61% | 8.21% | 12.67% | $59.44 / $34.08 | $11.22 |
| 7. | Moderna, Inc. | $59.66 | — | $23.63 B | — | -29.7% | -36.73% | $85.6 / $22.28 | $21.95 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 185.21 M | 169.06 M | 154.69 M | 125.25 M | 149.71 M | — |
| Operating Profit | 15.95 M | 34.27 M | -7.77 M | -7.95 M | 15.97 M | — |
| Net Profit | 1.69 M | 17.31 M | -24.42 M | -21.69 M | 14.74 M | — |
| EPS in Rs | 0.01 | 0.06 | -0.08 | -0.07 | 0.05 | -0.02 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 634.21 M | 528.29 M | 399.36 M | 329.23 M |
| Operating Profit | 34.49 M | 34.06 M | -73.49 M | -204.43 M |
| Net Profit | -27.11 M | -56.11 M | -151.58 M | -236.57 M |
| EPS in Rs | -0.09 | -0.18 | -0.48 | -0.75 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 949.87 M | 785.03 M | 777.88 M | 724.17 M |
| Total Liabilities | 675.63 M | 590.99 M | 617.71 M | 601.12 M |
| Equity | 274.24 M | 194.04 M | 160.17 M | 123.05 M |
| Current Assets | 676.17 M | 504.74 M | 483.06 M | 423.82 M |
| Current Liabilities | 237.83 M | 148.7 M | 167.69 M | 139.02 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 33.15 M | -33.89 M | -69.09 M | -166.57 M |
| Investing CF | -46.43 M | -0.56 M | 98.06 M | 92.32 M |
| Financing CF | 0.61 M | 5.12 M | 61.68 M | -7.46 M |
| Free CF | 29.85 M | -37.44 M | -76.53 M | -170.34 M |
| Capex | -3.3 M | -3.55 M | -7.44 M | -3.77 M |
5Y Margin & Growth History
Last 5 years of annual financial statement data.
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 32.29% | 21.3% | — | — |
| Earnings Growth % | 62.99% | 35.92% | — | — |
| Profit Margin % | -10.62% | -37.96% | -71.85% | — |
| Operating Margin % | 6.45% | -18.4% | -62.09% | — |
| Gross Margin % | 89.98% | 90.65% | 88.28% | — |
| EBITDA Margin % | 5.56% | -23.06% | -60.62% | — |
Dividend & Split History
Latest dividend payments and stock split events.
Dividend History
No dividend history available.
Stock Splits
No stock split history available.